On the contrary, the frequency of CD19+CD24−CD38− new memory B cells (from CD19+ B cells) decreased in the CHC-N, CHC-LC, and CHC-HCC patients compared with the healthy controls (mean, 15 ± 3, 17.3 ± 3, 10 ± 3 vs. 32 ± 4, p = 0.001, p = 0.005, p < 0.0001, respectively) and was somewhat lower in both the CHC-N and CHC-HCC patients than in the CHC-LC patients. This evidence concerns the gene CD19 and hepatocellular carcinoma.